The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer

被引：53

作者：

Huober, J ^{[1
]}

Meyer, A ^{[1
]}

Wagner, U ^{[1
]}

Wallwiener, D ^{[1
]}

机构：

[1] Univ Tubingen, Dept Obstet & Gynecol, D-72076 Tubingen, Germany

来源：

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 2002年 / 128卷 / 03期

关键词：

advanced ovarian cancer; neoadjuvant chemotherapy; interval laparotomy;

D O I：

10.1007/s00432-001-0312-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Radical debulking surgery allows for optimal cytoreduction in less than 50% of patients with advanced ovarian cancer. In spite of highly efficient chemotherapeutic regimens, the prognosis of patients with residual tumor masses larger than 1 cm in diameter following staging laparotomy is very poor. This observation led to the initiation of numerous trials evaluating the feasibility and efficiency of the use of primary chemotherapy followed by interval laparotomy in women with advanced ovarian cancer. The available data is presented and discussed in this review.

引用

页码：153 / 160

页数：8

共 47 条

[21]

HUOBER J, 2000, J CANC RES CLIN ONCO, V126

[22] NEOADJUVANT CHEMOTHERAPY AND INTERVAL DEBULKING FOR ADVANCED EPITHELIAL OVARIAN-CANCER [J].

JACOB, JH ;

GERSHENSON, DM ;

MORRIS, M ;

COPELAND, LJ ;

BURKE, TW ;

WHARTON, JT .

GYNECOLOGIC ONCOLOGY, 1991, 42 (02) :146-150

[23] Epithelial ovarian carcinoma [J].

Kristensen, GB ;

Trope, C .

LANCET, 1997, 349 (9045) :113-117

[24] Cancer statistics, 1999 [J].

Landis, SH ;

Murray, T ;

Bolden, S ;

Wingo, PA .

CA-A CANCER JOURNAL FOR CLINICIANS, 1999, 49 (01) :8-31

[25]

LAWTON FG, 1989, OBSTET GYNECOL, V73, P61

[26] Does debulking surgery improve survival in biologically aggressive ovarian carcinoma? [J].

Le, T ;

Krepart, GV ;

Lotocki, RJ ;

Heywood, MS .

GYNECOLOGIC ONCOLOGY, 1997, 67 (02) :208-214

[27]

Lim J T, 1993, Clin Oncol (R Coll Radiol), V5, P198, DOI 10.1016/S0936-6555(05)80227-4

[28]

McGuire WP, 1998, SEMIN ONCOL, V25, P340

[29] Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer [J].

McGuire, WP ;

Hoskins, WJ ;

Brady, MF ;

Kucera, PR ;

Partridge, EE ;

Look, KY ;

ClarkePearson, DL ;

Davidson, M .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (01) :1-6

[30] RANDOMIZED TRIAL COMPARING 2 COMBINATION CHEMOTHERAPY REGIMENS (CHAP-5 V CP) IN ADVANCED OVARIAN-CARCINOMA [J].

NEIJT, JP ;

TENBOKKELHUININK, WW ;

VANDERBURG, MEL ;

VANOOSTEROM, AT ;

WILLEMSE, PHB ;

HEINTZ, APM ;

VANLENT, M ;

TRIMBOS, JB ;

BOUMA, J ;

VERMORKEN, JB ;

VANHOUWELINGEN, JC .

JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (08) :1157-1168

← 1 2 3 4 5 →